Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis: A case report treated with high doses (8 mg/kg/d) of anakinra

Medicine (Baltimore). 2017 Jun;96(24):e6656. doi: 10.1097/MD.0000000000006656.

Abstract

Rationale: Myocarditis is a rare but potentially fatal complication of Still's disease (about 7% of total cases).

Patient concerns: A 42-year-old woman was admitted to our ward with high-grade fever, rash and polyarthralgia, lasting since 4 weeks and rapidly complicated by MAS and acute heart failure.

Diagnoses: Adult Onset Still's Disease rapidly developping macrophage activation syndrome and disseminated intravascular coagulopathy, further complicated by iperacute myocarditis with cardiac arrest.

Interventions: After failure of conventional therapies (steroids plus cyclosporine and then biological therapy with Anakinra 100 mg/day), the patient was treated with anakinra 100 mg sc 1 fl 4 times a day.

Outcomes: Fast clinical and laboratoristic improvement and subsequent disease remission with complete recovery of cardiac function.

Lessons: This is the first case report in which high doses of Anakinra have been used to treat a refractory AOSD complicated by MAS and myocarditis. In AOSD complicated by life-threatening conditions, probably we need to consider aggressive therapeutic approaches with higher doses of Il-1 receptor blocker to switch off the hyper-inflammation.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antirheumatic Agents / therapeutic use*
  • Drug Resistance
  • Female
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use*
  • Macrophage Activation Syndrome / complications*
  • Macrophage Activation Syndrome / drug therapy
  • Myocarditis / complications*
  • Myocarditis / drug therapy
  • Still's Disease, Adult-Onset / complications*
  • Still's Disease, Adult-Onset / drug therapy*

Substances

  • Antirheumatic Agents
  • Interleukin 1 Receptor Antagonist Protein